Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) has been assigned a consensus rating of “Moderate Buy” from the thirteen ratings firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have assigned a buy rating and two have issued a strong buy rating on the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $21.3636.

Several equities analysts have weighed in on the stock. UBS Group set a $18.00 target price on shares of Compass Pathways in a report on Thursday, May 7th. Wall Street Zen upgraded shares of Compass Pathways from a “strong sell” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Compass Pathways in a report on Monday, April 20th. BTIG Research reiterated a “buy” rating and set a $14.00 price target on shares of Compass Pathways in a report on Wednesday, May 13th. Finally, B. Riley Financial initiated coverage on shares of Compass Pathways in a report on Friday, April 24th. They set a “buy” rating and a $17.00 price target for the company.

Compass Pathways Stock Performance

NASDAQ:CMPS opened at $11.92 on Friday. The company has a current ratio of 3.32, a quick ratio of 3.32 and a debt-to-equity ratio of 0.15. The firm has a 50-day moving average price of $8.08 and a two-hundred day moving average price of $7.08. Compass Pathways has a twelve month low of $2.25 and a twelve month high of $12.48. The company has a market capitalization of $1.61 billion, a P/E ratio of -3.78 and a beta of 2.39.

Compass Pathways (NASDAQ:CMPS) last posted its earnings results on Wednesday, May 13th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.15. As a group, research analysts expect that Compass Pathways will post -1.24 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Compass Pathways

A number of hedge funds and other institutional investors have recently modified their holdings of CMPS. Royal Bank of Canada grew its holdings in shares of Compass Pathways by 49.8% during the first quarter. Royal Bank of Canada now owns 89,446 shares of the company’s stock worth $256,000 after buying an additional 29,733 shares in the last quarter. Acadian Asset Management LLC grew its holdings in Compass Pathways by 42.0% in the first quarter. Acadian Asset Management LLC now owns 240,591 shares of the company’s stock valued at $686,000 after purchasing an additional 71,112 shares during the period. Nantahala Capital Management LLC grew its holdings in Compass Pathways by 47.7% in the second quarter. Nantahala Capital Management LLC now owns 4,179,930 shares of the company’s stock valued at $11,704,000 after purchasing an additional 1,350,698 shares during the period. Balyasny Asset Management L.P. increased its position in Compass Pathways by 38.0% during the second quarter. Balyasny Asset Management L.P. now owns 854,840 shares of the company’s stock worth $2,394,000 after purchasing an additional 235,345 shares during the last quarter. Finally, Northeast Financial Consultants Inc purchased a new position in Compass Pathways during the second quarter worth approximately $59,000. 46.19% of the stock is currently owned by hedge funds and other institutional investors.

About Compass Pathways

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.